Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Doctors visit a patient in the First People's Hospital of Yancheng in Yancheng. Photo: Xinhua/via Getty Images
China wants to have better health care at a lower cost than the U.S. or other countries — a plan that involves extracting massive discounts from pharmaceutical companies, Bloomberg reports.
Why it matters: The trade-off for drug companies is access to China's enormous population and, thus, a giant market, and Chinese patients are now paying much less than Americans for the same drugs.
- At the same time, there's been a surge of venture capital funding within China's startup biotech industry, while the biggest global drug companies receive a growing share of their revenue from China.
The bottom line: "China has set its sights on creating a holy grail healthcare system that satisfies patients' needs and control costs while still encouraging cutting-edge research — and the world is watching," Bloomberg writes.